Bin CaoThuan T. TanEdwin PoonJann Tay WangSuresh KumarChong H.Kin LiamKamal AhmedPatrick MoralHaibo QiuMarie Yvette BarezLatre BuntaranOloan E. TampubolonVisanu ThamlikitkulBeijing Red Cross Chaoyang HospitalSingapore General HospitalPrivate PracticeNational Taiwan University HospitalHospital Sungai BulohUniversity of MalayaLiaquat National HospitalUniversity of Santo Tomas, ManilaSoutheast UniversityDavao Doctors Hospital'Harapan Kita' Heart HospitalIntensivistMahidol University2018-11-232018-11-232015-04-01Clinical Respiratory Journal. Vol.9, No.2 (2015), 129-1421752699X175269812-s2.0-84926337206https://repository.li.mahidol.ac.th/handle/20.500.14594/36482© 2014 John Wiley & Sons Ltd. Nosocomial pneumonia (NP; encompassing hospital-acquired, health care-associated and ventilator-associated pneumonia) is one of the most common nosocomial infections and is associated with a mortality rate of 18.7%-40.8% in Asian countries. The burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in Asia is high, and approximately 13% of NP cases in Asia are caused by this pathogen. Evidence regarding optimal management of MRSA NP continues to evolve and is complicated by the fact that a significant proportion of cases are likely to be caused by isolates with reduced susceptibility to the main therapeutic agent, vancomycin. The Asian Consensus Taskforce on MRSA Nosocomial Pneumonia has developed this statement to provide consensus points on diagnosis, antimicrobial treatment and prevention strategies for MRSA NP in the Asian context, based on our review of Asian data, previous international guidelines and recent scientific evidence.Mahidol UniversityMedicineArticleSCOPUS10.1111/crj.12134